Abstract Objective Cardiac involvement (CI) is a major determinant of poor prognosis in idiopathic inflammatory myopathies (IIM). Soluble suppression of tumorigenicity 2 (sST2) is a biomarker linked to cardiac inflammation and remodelling, but its role has scarcely been explored in IIM. We aimed to investigate the levels of sST2 and its longitudinal profile in patients with IIM and CI. Methods Serum sST2 levels were measured longitudinally over the course of two years in 34 patients with newly diagnosed IIM and in 109 patients with established IIM from a cross-sectional cohort, as well as in age and gender matched healthy controls (HC) and in patients with rheumatoid arthritis (RA). CI was assessed using cardiac magnetic resonance (CMR) in newly diagnosed IIM patients. Associations between sST2 and clinical parameters were analyzed. Results Patients with newly diagnosed IIM exhibited significantly higher sST2 levels at diagnosis compared to HC (P < 0.0001) and patients with established IIM (P < 0.0001). sST2 levels were highest at diagnosis, decreased significantly by 6 months, and remained lower during follow-up. sST2 levels were positively associated with cardiac troponin I and N-terminal pro-brain natriuretic peptide (P = 0.0001 and P = 0.0001, respectively). Importantly, IIM patients with active CMR-verified CI exhibited significantly higher sST2 levels than those without ongoing CI. In contrast, patients with established IIM had sST2 levels comparable to HC and RA patients. Conclusion sST2 is elevated in early IIM and closely associated with cardiac biomarkers and CMR-verified cardiac inflammation. Its dynamic decline with treatment suggests potential utility as a biomarker for early detection and monitoring of CI in IIM.
BACKGROUND:Obstructive sleep apnea (OSA) is associated with autonomic dysfunction and increased cardiovascular risk, but the effects of continuous positive airway pressure (CPAP) on exercise-derived autonomic responses in patients with coronary artery disease (CAD) remain unclear. METHODS:This study included nonsleepy patients (Epworth Sleepiness Scale score <10) with CAD and OSA (apnea-hypopnea index ≥15 events/h) enrolled in the RICCADSA randomized controlled trial. Of 244 patients randomized at baseline, 204 (CPAP n = 100; no-CPAP n = 104) completed bicycle ergometer exercise testing at both 3 and 12 months and were included. The primary outcome was the change in 1-min heart rate recovery (HRR1) from 3 to 12 months; secondary outcomes included changes in 4-min heart rate recovery (HRR4), chronotropic response, and post-exercise recovery time. Longitudinal changes were analyzed using linear mixed-effects models adjusted for sex, body mass index (BMI), diabetes, and β-blocker use. RESULTS:HRR1 remained stable from 3 to 12 months in both groups (approximately 22-23 bpm), with no CPAP or time × treatment effects. HRR4 showed no differential change, remaining around 46-47 bpm. Chronotropic response was unchanged (chronotropic index approximately 0.74-0.76 in both groups). Exercise workload and peak heart rate remained stable over time and did not differ between groups. Post-exercise recovery time shortened significantly in the overall cohort (by approximately 0.3 min from 3 to 12 months) but was not CPAP-specific. Higher BMI and β-blocker use were independently associated with impaired late HRR and chronotropic response. CONCLUSIONS:In nonsleepy patients with CAD and OSA, CPAP does not modify exercise-derived autonomic or chronotropic responses, underscoring the need for complementary strategies targeting metabolic burden and cardiovascular conditioning.
Reduced rapid-eye movement (REM) sleep has been linked to increased mortality in the general population. We investigated whether diminished REM sleep is associated with higher mortality in adults with coronary artery disease (CAD) and obstructive sleep apnea (OSA). This secondary analysis of the RICCADSA trial included 356 revascularized CAD patients with OSA (apnea–hypopnea index [AHI] ≥ 15 events/h) and total sleep time (TST) ≥ 240 min on baseline polysomnography. Reduced REM sleep was defined as the lowest quartile of REM percentage. Cox proportional hazards models assessed the association between reduced REM sleep and mortality over a median 4.7-year follow-up. The lowest REM quartile corresponded to 8.7
BACKGROUND:Obstructive sleep apnea (OSA) frequently coexists with coronary artery disease (CAD) and may contribute to heart failure with preserved ejection fraction (HFpEF). Whether HFpEF-like features are reversible with continuous positive airway pressure (CPAP) therapy remains uncertain. METHODS:A total of 177 revascularized CAD patients with nonsleepy OSA (Epworth Sleepiness Scale score <10; apnea-hypopnea index [AHI] ≥15/h) from the RICCADSA cohort randomized to CPAP (n = 89) or no CPAP (n = 88) were included. HFpEF-like status was defined using a composite of five echocardiographic and biomarker criteria (≥2 positive). Multivariable logistic regression models were constructed to assess the association between CPAP therapy and HFpEF improvement, adjusting for age, sex, body mass index, AHI, hypertension, diabetes, log-transformed NT-proBNP, and E/e' ratio. RESULTS:HFpEF-like features were present in 126 patients (71.2%), with similar prevalence in the CPAP and no-CPAP groups (69.7% vs 72.7%). Among patients with HFpEF-like status at baseline, improvement at 12 month-follow-up occurred in 24 of 62 patients (38.7%) randomized to CPAP compared with 13 of 64 (20.3%) in the no-CPAP group (p = 0.023). In multivariable analysis, CPAP remained independently associated with HFpEF improvement (OR 2.85, 95% CI 1.13-7.22; p = 0.027). Higher baseline NT-proBNP was inversely associated with improvement (OR 0.37; p = 0.002), whereas E/e' was not independently predictive. CONCLUSIONS:CPAP therapy is independently associated with improvement in HFpEF-like features in patients with CAD and OSA, particularly among those with lower myocardial stress. These findings support the presence of a potentially modifiable HFpEF phenotype responsive to treatment of sleep-disordered breathing. TRIAL REGISTRATION:ClinicalTrials.gov (NCT00519597).
BACKGROUND:Obstructive sleep apnea (OSA) is highly prevalent in patients with coronary artery disease (CAD) and is associated with autonomic dysfunction and adverse cardiovascular outcomes. Exercise-derived autonomic markers provide an integrated assessment of cardiovascular autonomic regulation. Whether baseline OSA severity and longitudinal autonomic adaptation during continuous positive airway pressure (CPAP) therapy are influenced by daytime sleepiness remains unclear. METHODS:In the RICCADSA cohort, 322 patients with CAD were studied, including CPAP-treated patients with moderate-to-severe OSA classified as non-sleepy (Epworth Sleepiness Scale [ESS] <10; n = 100) or sleepy (ESS ≥10; n = 130), and a non-OSA reference group (apnea-hypopnea index [AHI] <5 events/h; n = 92). Standardized exercise testing was performed at 3 and 12 months. Outcomes included heart-rate recovery at 1 and 4 min (HRR1, HRR4), chronotropic response, and post-exercise recovery time. Baseline associations with AHI were examined using multivariable linear regression, and longitudinal changes were assessed using linear mixed-effects models. RESULTS:Higher baseline AHI was independently associated with lower HRR1, HRR4, and chronotropic response (all p < 0.05), independent of ESS. During follow-up, HRR1, HRR4, and chronotropic response showed no meaningful change, whereas recovery time shortened significantly over time (p < 0.01). Longitudinal trajectories did not differ by sleepiness status. CONCLUSIONS:OSA severity is linked to impaired autonomic capacity, while CPAP therapy selectively improves autonomic recovery dynamics. Sleepiness does not modify these adaptations, suggesting that CPAP enhances autonomic flexibility rather than reversing established autonomic impairment.